Evidence map›Paper›PMID 37009503›Full record

ReviewFrontiers in cellular and infection microbiology2023

Role of MHC class I pathways in

Karolina D Witt

Open access · goldFull text readReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Protein-Mediated Virulence in Mycobacterium tuberculosis.Advances in experimental medicine and biology · 2026
    Review
  4. RNA vaccines: The dawn of a new age for tuberculosis?Human vaccines & immunotherapeutics · 2025
    Review
  5. The Ubiquitination ofBiology · 2025
    Article
  6. Intracellular Pathogens: Infection, Immunity, and Intervention.Methods in molecular biology (Clifton, N.J.) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Karolina D WittPandemic Sciences Institute, University of Oxford, Oxford, United Kingdom.
University of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MHC class I antigen processing is an underappreciated area of nonviral host-pathogen interactions, bridging both immunology and cell biology, where the pathogen's natural life cycle involves little presence in the cytoplasm. The effective response to MHC-I foreign antigen presentation is not only cell death but also phenotypic changes in other cells and stimulation of the memory cells ready for the next antigen reoccurrence. This review looks at the MHC-I antigen processing pathway and potential alternative sources of the antigens, focusing on

Indexed as

Antigen PresentationMycobacterium tuberculosisAntigens, BacterialHistocompatibility Antigens Class IHumansAntigens, BacterialHistocompatibility Antigens Class IMycobacterium tuberculosis antigensantigen processingcytotoxic T cellshost-pathogen interactionsMHC-IMycobacterium tuberculosisvaccine

Identifiers

PMID37009503
PMCPMC10050577
OpenAlexW4324376623

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read15
reference markers read79
identifiers read18
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.